Silikotac Program News Today

Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease NOVA awarded €2.4 million to leverage Jinko®, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease   1 2 - to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of action of inolimomab   ElsaLys Biotech utilising in silico studies to ac...

Consortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host disease NOVA awarded €2.4 million to leverage Jinko, its best-in-class clinical trial simulation platform, to conduct in silico studies for graft-versus-host disease Research academic teams of the consortium - Institut de Recherche Saint Louis 1 2 - to receive €0.95 million for their collaborative work with ElsaLys on in vitro and in vivo mechanisms of ...